Study for people stopping long-acting injectable PrEP
Part of Immune system & allergy, Infections clinical trials.
This study follows people who are stopping long-acting injectable PrEP (cabotegravir or lenacapavir). It checks how long the drug stays in your body and helps make sure you stay protected during that time. You'll do monthly video visits, mail in blood samples, and fill out short surveys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You are HIV-negative (to your knowledge)
- You can read and speak English
- You have a device (like a smartphone or computer) with internet for video calls
- You have a private spot at home for video calls
- You are thinking about stopping long-acting injectable PrEP (cabotegravir or lenacapavir), or have already stopped cabotegravir injections in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication, lenacapavir, to see how well it works for preventing HIV. It is for people who want or need PrEP (a medicine to prevent HIV) and are interested in learning about different options.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
This research studies how two types of long-acting birth control (a shot called cabotegravir and an implant) work in your body after pregnancy, and how they interact with HIV prevention or treatment. The study helps doctors understand the best doses and timing for women like you.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.